Application of comparative effectiveness research in evaluation of treatments for type 2 diabetes mellitus.

Andrew Ahmann

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Comparative effectiveness research (CER) is a relatively new strategy in drug development and healthcare designed to aid consumers, clinicians, purchasers, and policy makers in determining the best treatment options for individual patients. While defined in scope of clinical research, CER has the potential to be applied to other outcomes including economic evaluation of treatments and their potential impact on overall healthcare utilization by using all available data from clinical trials, systematic reviews, meta-analyses, and observational studies. Whereas clinical trials have mainly compared new agents with placebo (either alone or added to background therapy), CER compares new treatments head-to-head with active comparators to determine a patient's best available options. Because of the emphasis on the patient, and its potential to identify the best treatment options and produce substantial cost savings, CER is likely to be an integral part of American healthcare reform. The Affordable Care Act's emphasis on CER should benefit patients with type 2 diabetes (T2DM), a major chronic disease that affects 26 million Americans. The most recent innovations in marketed T2DM therapies include 2 classes of drugs focused on the incretin system: glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. This article reviews available CER among the incretin-based agents and for older T2DM therapies. CER is expected to open new avenues for research to clarify best practices in the treatment of T2DM, as well as possibly reduce treatment costs and improve the overall quality of public health.

Original languageEnglish (US)
JournalThe American journal of managed care
Volume17
Issue number2 Suppl
StatePublished - Mar 2011

Fingerprint

Comparative Effectiveness Research
Type 2 Diabetes Mellitus
Incretins
Therapeutics
Clinical Trials
Patient Protection and Affordable Care Act
Dipeptidyl-Peptidase IV Inhibitors
Delivery of Health Care
Health Care Reform
Cost Savings
Administrative Personnel
Practice Guidelines
Research
Pharmaceutical Preparations
Health Care Costs
Cost-Benefit Analysis
Observational Studies
Meta-Analysis
Chronic Disease
Public Health

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Application of comparative effectiveness research in evaluation of treatments for type 2 diabetes mellitus. / Ahmann, Andrew.

In: The American journal of managed care, Vol. 17, No. 2 Suppl, 03.2011.

Research output: Contribution to journalArticle

@article{d75d5324570f41369a654a744f26cbbf,
title = "Application of comparative effectiveness research in evaluation of treatments for type 2 diabetes mellitus.",
abstract = "Comparative effectiveness research (CER) is a relatively new strategy in drug development and healthcare designed to aid consumers, clinicians, purchasers, and policy makers in determining the best treatment options for individual patients. While defined in scope of clinical research, CER has the potential to be applied to other outcomes including economic evaluation of treatments and their potential impact on overall healthcare utilization by using all available data from clinical trials, systematic reviews, meta-analyses, and observational studies. Whereas clinical trials have mainly compared new agents with placebo (either alone or added to background therapy), CER compares new treatments head-to-head with active comparators to determine a patient's best available options. Because of the emphasis on the patient, and its potential to identify the best treatment options and produce substantial cost savings, CER is likely to be an integral part of American healthcare reform. The Affordable Care Act's emphasis on CER should benefit patients with type 2 diabetes (T2DM), a major chronic disease that affects 26 million Americans. The most recent innovations in marketed T2DM therapies include 2 classes of drugs focused on the incretin system: glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. This article reviews available CER among the incretin-based agents and for older T2DM therapies. CER is expected to open new avenues for research to clarify best practices in the treatment of T2DM, as well as possibly reduce treatment costs and improve the overall quality of public health.",
author = "Andrew Ahmann",
year = "2011",
month = "3",
language = "English (US)",
volume = "17",
journal = "American Journal of Managed Care",
issn = "1088-0224",
publisher = "Ascend Media",
number = "2 Suppl",

}

TY - JOUR

T1 - Application of comparative effectiveness research in evaluation of treatments for type 2 diabetes mellitus.

AU - Ahmann, Andrew

PY - 2011/3

Y1 - 2011/3

N2 - Comparative effectiveness research (CER) is a relatively new strategy in drug development and healthcare designed to aid consumers, clinicians, purchasers, and policy makers in determining the best treatment options for individual patients. While defined in scope of clinical research, CER has the potential to be applied to other outcomes including economic evaluation of treatments and their potential impact on overall healthcare utilization by using all available data from clinical trials, systematic reviews, meta-analyses, and observational studies. Whereas clinical trials have mainly compared new agents with placebo (either alone or added to background therapy), CER compares new treatments head-to-head with active comparators to determine a patient's best available options. Because of the emphasis on the patient, and its potential to identify the best treatment options and produce substantial cost savings, CER is likely to be an integral part of American healthcare reform. The Affordable Care Act's emphasis on CER should benefit patients with type 2 diabetes (T2DM), a major chronic disease that affects 26 million Americans. The most recent innovations in marketed T2DM therapies include 2 classes of drugs focused on the incretin system: glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. This article reviews available CER among the incretin-based agents and for older T2DM therapies. CER is expected to open new avenues for research to clarify best practices in the treatment of T2DM, as well as possibly reduce treatment costs and improve the overall quality of public health.

AB - Comparative effectiveness research (CER) is a relatively new strategy in drug development and healthcare designed to aid consumers, clinicians, purchasers, and policy makers in determining the best treatment options for individual patients. While defined in scope of clinical research, CER has the potential to be applied to other outcomes including economic evaluation of treatments and their potential impact on overall healthcare utilization by using all available data from clinical trials, systematic reviews, meta-analyses, and observational studies. Whereas clinical trials have mainly compared new agents with placebo (either alone or added to background therapy), CER compares new treatments head-to-head with active comparators to determine a patient's best available options. Because of the emphasis on the patient, and its potential to identify the best treatment options and produce substantial cost savings, CER is likely to be an integral part of American healthcare reform. The Affordable Care Act's emphasis on CER should benefit patients with type 2 diabetes (T2DM), a major chronic disease that affects 26 million Americans. The most recent innovations in marketed T2DM therapies include 2 classes of drugs focused on the incretin system: glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. This article reviews available CER among the incretin-based agents and for older T2DM therapies. CER is expected to open new avenues for research to clarify best practices in the treatment of T2DM, as well as possibly reduce treatment costs and improve the overall quality of public health.

UR - http://www.scopus.com/inward/record.url?scp=80051774401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051774401&partnerID=8YFLogxK

M3 - Article

C2 - 21517656

AN - SCOPUS:80051774401

VL - 17

JO - American Journal of Managed Care

JF - American Journal of Managed Care

SN - 1088-0224

IS - 2 Suppl

ER -